,,ii  #aagth ,,congress  #ast ,session  
,s4 #bdie  ,,in ,,the ,,senate ,,of     
,,the ,,united ,,states  ,july #bh1     
#bjba,mr4 ,cotton 7for himself1 ,mrs4   
,blackburn1 ,mr4 ,cruz1 ,mr4 ,scott of  
,florida1 and ,mr4 ,braun7 introduced   
the following bill2 which was read twice
 and referred to the ,committee on      
,finance  ,a ,,bill  ,to require the    
,secretary of ,health and ,human        
,services to maintain a list of the     
country of origin of all drugs marketed 
in the ,united ,states1 to ban the use  
of ,federal funds for the purchase of   
drugs manufactured in the ,people's     
,republic of ,china1 and for other      
purposes4  #a4 ,short title ,this ,act  
may be cited as the ,protecting our     
,pharmaceutical ,supply ,chain from     
,china ,act of #bjba4  #b4 ,country of  
origin of drugs  7a7 ,in general        
,subchapter ,a of chapter ,v of the     
,federal ,food1 ,drug1 and ,cosmetic    
,act 7#ba ,u4,s4,c4 #cea et seq47 is    
amended by adding at the end the        

following3  #ebd;,b4 ,registry of drugs 
produced outside the ,,us  7a7 ,in      
general ,the ,secretary shall compile   
and maintain a list of all drugs        
approved under subsection 7c7 or 7j7 of 
section #eje of this ,act or licensed   
under subsection 7a7 or 7k7 of section  
#cea of the ,public ,health ,service    
,act1 and any active ingredients in such
 drugs1 that-- 7#a7 are manufactured    
outside of the ,united ,states2 and     
7#b7 are determined by the ,secretary to
 be critical to the health and safety of
 consumers in the ,united ,states4  7b7 
,additional list ,in conjunction with   
the list described in subsection 7a71   
the ,secretary shall compile and        
maintain a list of drugs included on    
such list that are exclusively produced 
in1 or use active or inactive           
ingredients produced in1 the ,people's  
,republic of ,china4  7c7 ,requirement  
,the list described in subsection 7a7   
shall1 with respect to each drug        
included on the list1 provide           

information about the supply chain of   
the drug1 including each step in the    
supply chain that occurs prior to       
importation of the drug into the ,united
 ,states4  4  7b7 ,federal health       
program purchase of drugs  7#a7 ,in     
general ,notwithstanding any other      
provision of law1 the ,department of    
,health and ,human ,services1 the       
,department of ,veterans ,affairs1 the  
,department of ,defense1 and any other  
,federal health care program 7as defined
 in section #aabh;,b7f7 of the ,social  
,security ,act 7#db ,u4,s4,c4           
#acbj;a-#g;b7b7771 with respect to the  
purchase of a drug by such agency or    
program1 the following shall apply3 7,a7
 ,beginning on ,january #a1 #bjbc1 such 
agency or program may purchase only     
drugs for which #fj percent or more of  
the active pharmaceutical ingredients   
are manufactured in countries described 
in paragraph 7#b74  7,b7 ,beginning on  
,january #a1 #bjbd1 such agency or      
program may purchase only drugs for     

which #ajj percent of the active        
pharmaceutical ingredients are          
manufactured in countries described in  
paragraph 7#b74  7#b7 ,countries        
described ,the countries described in   
this paragraph are countries-- 7,a7     
other than ,people's ,republic of       
,china2 and  7,b7 that meet the health  
and safety standards of the ,food and   
,drug ,administration4  7#c7 ,waivers   
,the ,secretary of ,health and ,human   
,services may issue waivers of the      
requirements under paragraph 7#a7 for   
any agency or program that is unable to 
meet such requirements and demonstrates 
a need for the waiver4 ,no waiver may be
 issued under this paragraph for drugs  
that are purchased on or after ,january 
#a1 #bjbf4  7c7 ,labeling requirement   
,section #ejb of the ,federal ,food1    
,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4
 #ceb7 is amended by adding at the end  
the following3  7gg7 ,if it is a drug   
and its labeling does not specify the   
country of origin of each active        

ingredient contained in the drug4  4    
#c4 ,temporary #ajj percent expensing   
for pharmaceutical and medical device   
manufacturing property  7a7 ,in general 
,for purposes of section #afh7k7 of the 
,internal ,revenue ,code of #aihf1 in   
the case of any qualified pharmaceutical
 and medical device manufacturing       
property which is placed in service     
after ,december #ca1 #bjai1 and before  
,january #a1 #bjbg-- 7#a7 such property 
shall be treated as qualified property  
7within the meaning of such section71   
7#b7 the applicable percentage otherwise
 determined under section #afh7k77#f7 of
 such ,code with respect to such        
property shall be #ajj percent1 and     
7#c7 paragraph 7#h7 of such section     
shall not apply4  7b7 ,qualified        
pharmaceutical and medical device       
manufacturing property ,for purposes of 
this section1 the term qualified        
pharmaceutical and medical device       
manufacturing property means any        
tangible property placed in service in  

the ,united ,states as part of the      
construction or expansion of property   
for the manufacture of drugs 7as defined
 in section #bja7;g7 of the ,federal    
,food1 ,drug1 and ,cosmetic ,act 7#ba   
,u4,s4,c4 #cba7;g777 or medical devices 
7as defined in section #bja7;h7 of such 
,act 7#ba ,u4,s4,c4 #cba7;h7774